FDA Bans Sneaky Drug Importer Jeremy Spencer Brown
Published Date: 2/12/2026
Notice
Summary
Jeremy Spencer Brown is banned for 5 years from importing any drugs into the U.S. because he was convicted of trying to bring in unapproved drugs with the intent to trick people. He didn’t respond to the FDA’s notice, so the ban started on February 12, 2026. He can apply to end this ban anytime, but must follow special rules to keep any private info safe.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Five-Year Ban on Drug Importing
Jeremy Spencer Brown is barred for 5 years from importing or offering for import any drug into the United States, effective February 12, 2026. The debarment is based on his February 3, 2025 felony conviction for introduction of unapproved drugs into interstate commerce with intent to defraud or mislead.
Assisting His Imports Is Prohibited
Under section 301(cc) of the FD&C Act, importing or offering for import any drug into the U.S. by, with the assistance of, or at the direction of Jeremy Spencer Brown is a prohibited act as of February 12, 2026. That prohibition makes it unlawful for others to help him import drugs during the debarment period.
How to Seek Removal and Privacy Rules
Mr. Brown may apply to end the debarment at any time by submitting an application (Docket No. FDA-2025-N-0435). Electronic applications submitted to https://www.regulations.gov will be posted publicly unchanged, so confidential information must not be included in electronic filings; to submit confidential information, send a written/paper submission with two copies—one marked "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION" and one redacted copy for public viewing.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20730, Elite Laboratories, Inc. et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications; Correction
The FDA fixed a previous announcement about pulling approval for 16 generic drug applications. Three drugs from Navinta LLC—ribavirin solution, fosaprepitant powder, and nicardipine capsules—won't lose approval because Navinta asked to keep them active. This means those three drugs stay on the market, while the other 13 still had their approvals withdrawn as planned back in July 2026.
Previous / Next Documents
Previous: 2026-02785, Agency Information Collection Activities; Submission for OMB Review; Comment Request; Annual Information Return/Report of Employee Benefit Plan
The Department of Labor is asking for public feedback on the yearly report that companies must file about their employee benefit plans. This report helps keep retirement and health plans running smoothly and fairly. Comments are open until March 16, 2026, so plan administrators and anyone interested should speak up now!
Next: 2026-02787, Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-United States (U.S.) 2026-2027 Influenza Vaccine Strain Composition
The FDA is hosting a public meeting on March 12, 2026, to decide which flu virus strains will be included in the 2026-2027 flu vaccine. This affects everyone who gets a flu shot, helping make sure the vaccine matches the most common flu types. They’re also asking for your thoughts before March 11, so speak up and help shape next year’s flu protection!